PTP1B / TC-PTP dual inhibitor and protein degradation agent
By designing a dual inhibitor of PTP1B/TC-PTP and a protein degrader, the complexity of existing PTP1B and TC-PTP combination therapies has been resolved. This approach achieves synergistic inhibition and degradation of PTP1B and TC-PTP, simplifying treatment protocols and improving efficacy and safety.
CN121079098APending Publication Date: 2025-12-05PURDUE RES FOUND
24 Cites 0 Cited by
Patent Information
- Application Number
- CN202380096863.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-06
- Filing Date
- 2023-12-08
- Publication Date
- 2025-12-05
AI Technical Summary
Technical Problem
Existing technologies have difficulty effectively targeting the two enzymes, PTP1B and TC-PTP, leading to pharmacokinetic/pharmacodynamic complexities, drug interactions, and toxicity issues in combination therapies for type II diabetes, obesity, and anticancer immunotherapy.
Method used
We have developed dual inhibitors of PTP1B and TC-PTP and protein degraders, providing multi-target drug solutions by designing compounds with specific structures to simultaneously inhibit and degrade PTP1B and TC-PTP enzymes.
Benefits of technology
It achieves synergistic inhibition and degradation of PTP1B and TC-PTP, simplifies treatment regimens, reduces the risk of drug interactions, and improves treatment efficacy and patient compliance.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to compounds that are dual inhibitors and dual degradation agents of protein tyrosine phosphatase 1B (PTP1B) and T cell protein tyrosine phosphatase (TC-PTP); compositions comprising the compounds; and their use in the treatment of diseases or conditions mediated by PTP1B and TC-PTP.
Need to check novelty before this filing date? Find Prior Art